Security assessments indicated that gastrointestinal adverse situations, largely nausea and diarrhea, ended up dose-dependent but normally gentle and transient. These findings established the therapeutic window and educated dose choice for subsequent Stage 3 trials.Numerous human cytokines will produce a pleasant response in mouse mobile traces, an